Archives of Pharmacal Research

, Volume 33, Issue 10, pp 1557–1565

How to overcome retinal neuropathy: The fight against angiogenesisrelated blindness


DOI: 10.1007/s12272-010-1007-6

Cite this article as:
Jo, D.H., Kim, J.H. & Kim, J.H. Arch. Pharm. Res. (2010) 33: 1557. doi:10.1007/s12272-010-1007-6


The retina consists of neuronal cells of high metabolic activity that are supplied by an abundant vasculature. It is a main theme of ophthalmologic research, because retinopathies are common causes of blindness in all age groups: age-related macular degeneration in the elderly, diabetic retinopathy in the middle aged, and retinopathy of prematurity and retinoblastoma in children. Interestingly, angiogenesis underlies the pathogenesis of all these diseases, and breakdown of the blood-retinal barrier is also thought to play an important role before and throughout the process of new vessel formation. However, so far, most treatments have targeted angiogenesis only, especially vascular endothelial growth factor. Consideration of the restoration of the blood-retinal barrier should be required. In this review, we discuss the clinical manifestation, pathogenesis, and current treatment options for angiogenesis-related blindness. In addition, because of the recent introduction of novel strategies, we describe pathogenesis-based treatment options to treat angiogenesis-related blindness.

Key words

Angiogenesis-related blindnessAge-related macular degenerationDiabetic retinopathyRetinoblastomaRetinopathy of prematurity

Copyright information

© The Pharmaceutical Society of Korea and Springer Netherlands 2010

Authors and Affiliations

  • Dong Hyun Jo
    • 1
    • 2
  • Jin Hyoung Kim
    • 2
  • Jeong Hun Kim
    • 1
    • 2
    • 3
  1. 1.Department of Ophthalmology, College of MedicineSeoul National UniversitySeoulKorea
  2. 2.Fight against Angiogenesis-Related Blindness (FARB) laboratory, Department of Ophthalmology, College of MedicineSeoul National UniversitySeoulKorea
  3. 3.FARB (Fight against Angiogenesis-Related Blindness) Laboratory, Department of OphthalmologySeoul National University College of Medicine and Seoul Artificial Eye Center, Clinical Research Institute, Seoul National University HospitalSeoulKorea